SCHEMBL3407236

SCHEMBL3407236

Cc1cc(OCc2ccccc2)c(C(=O)C=Cc2ccc(N)cc2)c(OCc2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 1/20 0.55
▸ PDE4B Q07343 1/20 0.55
▸ PDE4C Q08493 1/20 0.55
▸ PDE4D Q08499 1/20 0.55
▸ SLC5A1 P13866 1/20 0.55
▸ SLC5A2 P31639 1/20 0.55
▸ LMNA P02545 2/20 0.49
▸ MAOB P27338 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ APP P05067 3/20 0.48
▸ ABCG2 Q9UNQ0 1/20 0.48
▸ GSK3B P49841 1/20 0.47
▸ BACE1 P56817 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ AKR1C3 P42330 1/20 0.46
▸ CYP1B1 Q16678 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1682158 0.87 MAOB (0.66) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL12808163 0.87 MAOB (0.66) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL14616680 0.87 LMNA (0.65) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL25217712 0.85 SLC5A1 (0.62) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL30384069 0.85 SLC5A1 (0.62) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL30384209 0.83 SLC5A1 (0.73) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL17523241 0.83 SLC5A1 (0.73) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL3409487 0.83 NPC1 (0.51) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL3409489 0.83 NPC1 (0.51) PDE4APDE4BPDE4CPDE4DSLC5A1
SCHEMBL17244808 0.81 SLC5A1 (0.64) PDE4APDE4BPDE4CPDE4DSLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816331-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA NV (BE) 2010-10-19 — — US disclosed
US-20100062971-A1 SUBSTITUTED INDAZOLE-O-GLUCOSIDES PATEL MONA 2010-03-11 — — US disclosed
EP-1680414-A4 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA NV (BE) 2009-05-27 — — EP disclosed
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES PATEL MONA 2009-04-16 — — US disclosed
US-7511021-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-31 — — US disclosed
US-20060217323-A1 Substituted indazole-O-glucosides Tanabe Pharma Corporation (JP) 2006-09-28 — — US disclosed
US-7084124-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-01 — — US disclosed
EP-1680414-A2 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-19 — — EP disclosed
US-20050032711-A1 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — US disclosed
WO-2005011592-A2 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032711-A1 Substituted indazole-O-glucosides GYS2, GPR119, UGGT1 PDE4A 2167/4885PDE4B 1726/4885PDE4C 2461/4885
US-20100062971-A1 SUBSTITUTED INDAZOLE-O-GLUCOSIDES GYS2, GPR119, UGGT1 PDE4A 2167/4885PDE4B 1726/4885PDE4C 2461/4885
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES GYS2, GPR119, PYGL PDE4A 2062/4885PDE4B 1653/4885PDE4C 2320/4885
US-20060217323-A1 Substituted indazole-O-glucosides GYS2, GPR119, UGGT1 PDE4A 2167/4885PDE4B 1726/4885PDE4C 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback